772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk
Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at low-to-moderate...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 73 |
| creator | PAIK, JULIE M. TESFAYE, HELEN JANE CROMER, SARA DICESARE, ELYSE O. ALIX, CAROLINE WEXLER, DEBORAH J. PATORNO, ELISABETTA |
| description | Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at low-to-moderate cardiovascular (CV) risk, a population that remains largely unexplored in clinical trials.
Methods: We estimated hazard ratios (HRs), rate differences (RD) and 95% confidence intervals (CI) of acute pancreatitis or biliary disease among 1:1 propensity score-matched adults initiating GLP1RA vs. dipeptidyl peptidase-4 inhibitor (DPP4i) or sodium glucose cotransporter 2 inhibitor (SGLT2i) in Medicare and 2 private health plans (2013-2023).
Results: Over a mean follow-up of ~11 months, the HR for pancreatitis in the GLP1RA group was 1.19 (95%CI 1.00-1.42; RD 0.20 per 1,000 person-years (PY) [0.01-0.39]) compared with the DPP4i group and 0.99 (0.82-1.20; RD -0.01 per 1,000 PY [-0.17-0.16]) compared with the SGLT2i group (Table). The HR for biliary disease in the GLP1RA group was 1.10 (0.96-1.26; RD 0.13 per 1,000 PY [-0.10-0.37]) compared with the DPP4i group and 1.12 (0.97-1.30; RD 0.22 per 1,000 PY [0.01-0.43]) in the SGLT2i group.
Conclusion: GLP1RA initiation was not associated with meaningful differences in the risk of acute pancreatitis or biliary disease in patients with T2D and low-to-moderate CV risk. |
| doi_str_mv | 10.2337/db24-772-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3111275624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111275624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c634-85d3caf4e07aa89837858660bed279405cbde46f55ad75bafda5f0e7ebc9904f3</originalsourceid><addsrcrecordid>eNotkF9LwzAUxYMoOKcvfoKAb0I1f5qm9W1OnULFMqb4FtLmBjNnO5OUsW9vt8l9uA_nd8_lHIQuKblhnMtbU7M0kZIl1REa0YIXCWfy8xiNCKEsobKQp-gshCUhJBtmhLZ7-A7PyorOJ_g9ANatwXMXvnFncaXbxoOOLrqwF-7dymm_xQ8ugB5g1-KJ6Vcx4I2LX3ixXQNmg6priHA4KbsNjh1-7Qx4HQFPP_b25-jE6lWAi_89Rounx8X0OSnfZi_TSZk0GU-TXBjeaJsCkVrnRc5lLvIsIzUYJouUiKY2kGZWCG2kqLU1WlgCEuqmKEhq-RhdHWzXvvvtIUS17HrfDh8Vp5QyKTKWDtT1gWp8F4IHq9be_QxBFSVq16zaNauGslTF_wB46mmJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111275624</pqid></control><display><type>article</type><title>772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk</title><source>EZB Electronic Journals Library</source><creator>PAIK, JULIE M. ; TESFAYE, HELEN ; JANE CROMER, SARA ; DICESARE, ELYSE O. ; ALIX, CAROLINE ; WEXLER, DEBORAH J. ; PATORNO, ELISABETTA</creator><creatorcontrib>PAIK, JULIE M. ; TESFAYE, HELEN ; JANE CROMER, SARA ; DICESARE, ELYSE O. ; ALIX, CAROLINE ; WEXLER, DEBORAH J. ; PATORNO, ELISABETTA</creatorcontrib><description>Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at low-to-moderate cardiovascular (CV) risk, a population that remains largely unexplored in clinical trials.
Methods: We estimated hazard ratios (HRs), rate differences (RD) and 95% confidence intervals (CI) of acute pancreatitis or biliary disease among 1:1 propensity score-matched adults initiating GLP1RA vs. dipeptidyl peptidase-4 inhibitor (DPP4i) or sodium glucose cotransporter 2 inhibitor (SGLT2i) in Medicare and 2 private health plans (2013-2023).
Results: Over a mean follow-up of ~11 months, the HR for pancreatitis in the GLP1RA group was 1.19 (95%CI 1.00-1.42; RD 0.20 per 1,000 person-years (PY) [0.01-0.39]) compared with the DPP4i group and 0.99 (0.82-1.20; RD -0.01 per 1,000 PY [-0.17-0.16]) compared with the SGLT2i group (Table). The HR for biliary disease in the GLP1RA group was 1.10 (0.96-1.26; RD 0.13 per 1,000 PY [-0.10-0.37]) compared with the DPP4i group and 1.12 (0.97-1.30; RD 0.22 per 1,000 PY [0.01-0.43]) in the SGLT2i group.
Conclusion: GLP1RA initiation was not associated with meaningful differences in the risk of acute pancreatitis or biliary disease in patients with T2D and low-to-moderate CV risk.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db24-772-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Cardiovascular diseases ; Clinical trials ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Gallbladder diseases ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Pancreatitis</subject><ispartof>Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>PAIK, JULIE M.</creatorcontrib><creatorcontrib>TESFAYE, HELEN</creatorcontrib><creatorcontrib>JANE CROMER, SARA</creatorcontrib><creatorcontrib>DICESARE, ELYSE O.</creatorcontrib><creatorcontrib>ALIX, CAROLINE</creatorcontrib><creatorcontrib>WEXLER, DEBORAH J.</creatorcontrib><creatorcontrib>PATORNO, ELISABETTA</creatorcontrib><title>772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk</title><title>Diabetes (New York, N.Y.)</title><description>Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at low-to-moderate cardiovascular (CV) risk, a population that remains largely unexplored in clinical trials.
Methods: We estimated hazard ratios (HRs), rate differences (RD) and 95% confidence intervals (CI) of acute pancreatitis or biliary disease among 1:1 propensity score-matched adults initiating GLP1RA vs. dipeptidyl peptidase-4 inhibitor (DPP4i) or sodium glucose cotransporter 2 inhibitor (SGLT2i) in Medicare and 2 private health plans (2013-2023).
Results: Over a mean follow-up of ~11 months, the HR for pancreatitis in the GLP1RA group was 1.19 (95%CI 1.00-1.42; RD 0.20 per 1,000 person-years (PY) [0.01-0.39]) compared with the DPP4i group and 0.99 (0.82-1.20; RD -0.01 per 1,000 PY [-0.17-0.16]) compared with the SGLT2i group (Table). The HR for biliary disease in the GLP1RA group was 1.10 (0.96-1.26; RD 0.13 per 1,000 PY [-0.10-0.37]) compared with the DPP4i group and 1.12 (0.97-1.30; RD 0.22 per 1,000 PY [0.01-0.43]) in the SGLT2i group.
Conclusion: GLP1RA initiation was not associated with meaningful differences in the risk of acute pancreatitis or biliary disease in patients with T2D and low-to-moderate CV risk.</description><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Gallbladder diseases</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Pancreatitis</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNotkF9LwzAUxYMoOKcvfoKAb0I1f5qm9W1OnULFMqb4FtLmBjNnO5OUsW9vt8l9uA_nd8_lHIQuKblhnMtbU7M0kZIl1REa0YIXCWfy8xiNCKEsobKQp-gshCUhJBtmhLZ7-A7PyorOJ_g9ANatwXMXvnFncaXbxoOOLrqwF-7dymm_xQ8ugB5g1-KJ6Vcx4I2LX3ixXQNmg6priHA4KbsNjh1-7Qx4HQFPP_b25-jE6lWAi_89Rounx8X0OSnfZi_TSZk0GU-TXBjeaJsCkVrnRc5lLvIsIzUYJouUiKY2kGZWCG2kqLU1WlgCEuqmKEhq-RhdHWzXvvvtIUS17HrfDh8Vp5QyKTKWDtT1gWp8F4IHq9be_QxBFSVq16zaNauGslTF_wB46mmJ</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>PAIK, JULIE M.</creator><creator>TESFAYE, HELEN</creator><creator>JANE CROMER, SARA</creator><creator>DICESARE, ELYSE O.</creator><creator>ALIX, CAROLINE</creator><creator>WEXLER, DEBORAH J.</creator><creator>PATORNO, ELISABETTA</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240614</creationdate><title>772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk</title><author>PAIK, JULIE M. ; TESFAYE, HELEN ; JANE CROMER, SARA ; DICESARE, ELYSE O. ; ALIX, CAROLINE ; WEXLER, DEBORAH J. ; PATORNO, ELISABETTA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c634-85d3caf4e07aa89837858660bed279405cbde46f55ad75bafda5f0e7ebc9904f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Gallbladder diseases</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Pancreatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PAIK, JULIE M.</creatorcontrib><creatorcontrib>TESFAYE, HELEN</creatorcontrib><creatorcontrib>JANE CROMER, SARA</creatorcontrib><creatorcontrib>DICESARE, ELYSE O.</creatorcontrib><creatorcontrib>ALIX, CAROLINE</creatorcontrib><creatorcontrib>WEXLER, DEBORAH J.</creatorcontrib><creatorcontrib>PATORNO, ELISABETTA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PAIK, JULIE M.</au><au>TESFAYE, HELEN</au><au>JANE CROMER, SARA</au><au>DICESARE, ELYSE O.</au><au>ALIX, CAROLINE</au><au>WEXLER, DEBORAH J.</au><au>PATORNO, ELISABETTA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2024-06-14</date><risdate>2024</risdate><volume>73</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Introduction & Objective: Glucagon-like peptide-1 receptor agonists (GLP1RA) may increase pancreatitis and biliary disease risk. We investigated the association between GLP1RA initiation and the risk of pancreatitis or biliary disease among patients with type 2 diabetes (T2D) at low-to-moderate cardiovascular (CV) risk, a population that remains largely unexplored in clinical trials.
Methods: We estimated hazard ratios (HRs), rate differences (RD) and 95% confidence intervals (CI) of acute pancreatitis or biliary disease among 1:1 propensity score-matched adults initiating GLP1RA vs. dipeptidyl peptidase-4 inhibitor (DPP4i) or sodium glucose cotransporter 2 inhibitor (SGLT2i) in Medicare and 2 private health plans (2013-2023).
Results: Over a mean follow-up of ~11 months, the HR for pancreatitis in the GLP1RA group was 1.19 (95%CI 1.00-1.42; RD 0.20 per 1,000 person-years (PY) [0.01-0.39]) compared with the DPP4i group and 0.99 (0.82-1.20; RD -0.01 per 1,000 PY [-0.17-0.16]) compared with the SGLT2i group (Table). The HR for biliary disease in the GLP1RA group was 1.10 (0.96-1.26; RD 0.13 per 1,000 PY [-0.10-0.37]) compared with the DPP4i group and 1.12 (0.97-1.30; RD 0.22 per 1,000 PY [0.01-0.43]) in the SGLT2i group.
Conclusion: GLP1RA initiation was not associated with meaningful differences in the risk of acute pancreatitis or biliary disease in patients with T2D and low-to-moderate CV risk.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db24-772-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2024-06, Vol.73 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_3111275624 |
| source | EZB Electronic Journals Library |
| subjects | Cardiovascular diseases Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Gallbladder diseases GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Pancreatitis |
| title | 772-P: GLP1RA Use and Risk of Pancreatitis and Biliary Disease in Adults with Type 2 Diabetes and Low to Moderate CV Risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A55%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=772-P:%20GLP1RA%20Use%20and%20Risk%20of%20Pancreatitis%20and%20Biliary%20Disease%20in%20Adults%20with%20Type%202%20Diabetes%20and%20Low%20to%20Moderate%20CV%20Risk&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=PAIK,%20JULIE%20M.&rft.date=2024-06-14&rft.volume=73&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db24-772-P&rft_dat=%3Cproquest_cross%3E3111275624%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111275624&rft_id=info:pmid/&rfr_iscdi=true |